Antibody-Targeted Precision Medicines
Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery of potent therapeutic agents. These modalities offer new opportunities in oncology and beyond but present complex challenges in design, conjugation, and optimization.
In this white paper, we examine the structural principles and technical hurdles that influence the success of antibody-targeted drugs and discuss strategies to mitigate risk and accelerate their development.
White Paper_Antibody-Targeted_Precision_Medicines_WuXi AppTec
Related Content
T-cell engagers (TCEs) are designed to redirect T cells toward tumor cells, offering a highly focused approach to immune-mediated killing....
VIEW RESOURCEBispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...
VIEW RESOURCE